The Mayo Clinic in Rochester, MN, is highlighting that the first breast cancer patient has been treated with a novel radiopharmaceutical therapy as part of a multisite clinical trial.
The phase IB/II open-label trial is being conducted at all three academic Mayo Clinic sites and about 20 other sites across the U.S., with the first person treated in Florida, the health system said.
The therapy contains actinium-225 (Ac-225), which works by passing through the blood to stick to cancer cells without harming healthy surrounding tissues.
The study is evaluating the potential of Ac-225 alone and with the immunotherapy drug pembrolizumab in women with ER+, HER2-negative, unresectable or metastatic breast cancer expressing somatostatin receptors.
